SecurityRDUS / Radius Health, Inc. (750469207)
IndustryPharmaceutical Preparations
Common Stock Shares Outstanding45,476,455 shares (as of 2018-06-30)
Total Insiders43
Total Directors12
Total Officers12

Stock Insider Trading (from SEC Form 4)

RDUS / Radius Health, Inc. Insider Trades

Radius Health, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

RDUS / Radius Health, Inc. insiders include MPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLC, Rosenberg Anthony, Scopa James Paul, Foley Todd, Roychowdhury Debasish, STEINMETZ MICHAEL, GADICKE ANSBERT, Hoiland Jesper, and Dere Willard H, KAILIAN VAUGHN M, MPM BIOVENTURES III L.P., SIMON NICHOLAS J III, HENNER DENNIS, AUERBACH ALAN H, Carmona Jose, Morris Charles Q Muenchbach Martin, FRIEDMAN CATHY, WHEELER KURT, Williams Gregory C., MPM BIOVENTURES III PARALLEL FUND, L.P., BIOTECH GROWTH N V, Hughes Owen, BB BIOTECH AG, MPM BIOVENTURES III LLC, MPM BioVentures IV GP LLC, MPM BIOVENTURES III GP L.P., Snow David P., Kelly Joseph Francis, Purandare Dinesh, Fitzpatrick Lorraine A., Ward Robert, Hattersley Gary, GALAKATOS NICHOLAS, Graves Kurt, EVNIN LUKE, Harvey Brian Nicholas, GARNIER JEAN PIERRE, Hatzis-Schoch Brent, MPM BIOVENTURES III GMBH & CO. Beteiligungs KG, MPM BIOVENTURES III-QP L.P., MPM Bio IV NVS Strategic Fund LP, MPM BioVentures IV LLC, .

Insider Roster

Insider Dir Off 10% Shares Owned
Morris Charles Q Chief Medical Officer
X 0
BIOTECH GROWTH N V 10% Owner
BB BIOTECH AG 10% Owner
X 6,590,276
BB BIOTECH AG 10% Owner
BIOTECH GROWTH N V 10% Owner
X 6,110,913
Williams Gregory C. Chief Development Officer
X
Rosenberg Anthony Director
X
Kelly Joseph Francis Sr. VP of Sales and Marketing
X
Hughes Owen Director
X
Hoiland Jesper President and CEO, Director
X X
Hatzis-Schoch Brent Sr. VP, General Counsel
X
Hattersley Gary Chief Scientific Officer
X
Graves Kurt Director
X
GARNIER JEAN PIERRE Director
X
FRIEDMAN CATHY Director
X
Dere Willard H Director
X
Carmona Jose Chief Financial Officer
X
Roychowdhury Debasish Director
X
Harvey Brian Nicholas Sr. VP and CFO
X 76,189
AUERBACH ALAN H Director
X
Purandare Dinesh SVP, Head of Global Oncology
X
GADICKE ANSBERT Director
X
Fitzpatrick Lorraine A. Chief Medical Officer
X
Ward Robert President & CEO, Director
X X
Snow David P. Chief Commercial Officer
X
Foley Todd
MPM BioVentures IV LLC
Scopa James Paul
MPM BioVentures IV GP LLC
MPM Bio IV NVS Strategic Fund LP
KAILIAN VAUGHN M
EVNIN LUKE
SIMON NICHOLAS J III
GALAKATOS NICHOLAS
WHEELER KURT
STEINMETZ MICHAEL
MPM BIOVENTURES III LLC
HENNER DENNIS
MPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLC
MPM BIOVENTURES III GMBH & CO. Beteiligungs KG
MPM BIOVENTURES III PARALLEL FUND, L.P.
MPM BIOVENTURES III GP L.P.
MPM BIOVENTURES III L.P.
MPM BIOVENTURES III-QP L.P.
Muenchbach Martin Director
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-08-20 4 BIOTECH GROWTH N V P D 19.6468 60,000 6,590,276 129,477,835
2018-08-15 4 BIOTECH GROWTH N V P D 20.7824 69,363 6,530,276 135,714,808
2018-08-14 4 BIOTECH GROWTH N V P D 20.8688 100,000 6,460,913 134,831,501
2018-08-08 4 BIOTECH GROWTH N V P D 22.7314 60,000 6,360,913 144,592,458
2018-07-27 4 BIOTECH GROWTH N V P D 24.8121 50,000 6,300,913 156,338,883
2018-07-25 4 BIOTECH GROWTH N V P D 27.2761 50,000 6,250,913 170,500,528
2018-06-11 4 BIOTECH GROWTH N V P D 27.3567 50,000 6,200,913 169,636,517
2018-05-23 4 BIOTECH GROWTH N V P D 28.908 40,000 6,150,913 177,810,593
2018-05-21 4 BIOTECH GROWTH N V P D 29.273 60,000 6,110,913 178,884,756
2018-04-19 4 BIOTECH GROWTH N V P D 33.7984 40,000 6,050,913 204,511,178
2018-04-12 4 BIOTECH GROWTH N V X D 14.004 107,114 6,010,913
2018-04-05 4 BIOTECH GROWTH N V P D 36.5769 50,000 5,903,799 215,942,666
2018-03-02 4 BIOTECH GROWTH N V P D 32.5181 80,000 5,853,799 190,354,421
2018-02-09 4 BIOTECH GROWTH N V P D 34.3835 75,000 5,773,799 198,523,418
2017-11-14 4 BIOTECH GROWTH N V P D 26.2478 50,000 5,698,799 149,580,936
2017-11-10 4 Hatzis-Schoch Brent P D 28.0893 1,778 2,278 63,987
2017-11-07 4 Hoiland Jesper P D 29.0368 6,800 12,900 374,575
2017-11-03 4 BIOTECH GROWTH N V P D 29.1515 50,000 5,648,799 164,670,964
2017-10-26 4 BIOTECH GROWTH N V P D 30.951 50,000 5,598,799 173,288,428
2017-10-25 4 BIOTECH GROWTH N V P D 32.8483 50,000 5,548,799 182,268,614
2017-09-15 4 Hoiland Jesper P D 32.7227 6,100 6,100 199,608
2017-09-14 4 Carmona Jose P D 32.8343 3,000 3,000 98,503
2017-09-14 4 BIOTECH GROWTH N V P D 32.9445 50,000 5,498,799 181,155,184
2017-09-13 4 BIOTECH GROWTH N V P D 33.7075 100,000 5,448,799 183,665,392
2017-09-12 4 BIOTECH GROWTH N V P D 35.4164 50,000 5,348,799 189,435,205
2017-09-05 4 BIOTECH GROWTH N V P D 36.7525 50,000 5,298,799 194,744,110
2017-08-16 4 BIOTECH GROWTH N V P D 35.9756 60,000 5,248,799 188,828,693
2017-08-10 4 BIOTECH GROWTH N V P D 34.26 75,000 5,188,799 177,768,254
2017-08-09 4 BIOTECH GROWTH N V P D 35.6737 75,000 5,113,799 182,428,131
2017-05-30 4 BIOTECH GROWTH N V P D 34.2087 40,000 5,038,799 172,370,763
2017-05-25 4 BIOTECH GROWTH N V P D 36.2505 40,000 4,998,799 181,208,963
2017-05-18 4 BIOTECH GROWTH N V P D 34.4069 50,000 4,958,799 170,616,901
2017-05-17 4 BIOTECH GROWTH N V P D 32.9812 18,000 4,908,799 161,898,082
2017-05-16 4 BIOTECH GROWTH N V P D 33.925 17,000 4,890,799 165,920,356
2017-05-12 4 BIOTECH GROWTH N V P D 33.9997 15,000 4,873,799 165,707,704
2017-05-09 4 BIOTECH GROWTH N V P D 35.9296 50,000 4,858,799 174,574,705
2017-05-08 4 BIOTECH GROWTH N V P D 35.5978 22,800 4,808,799 171,182,665
2017-05-05 4 BIOTECH GROWTH N V P D 35.5477 20,600 4,785,999 170,131,257
2017-05-02 4 BIOTECH GROWTH N V P D 33.9056 75,000 4,765,399 161,573,712
2017-05-01 4 BIOTECH GROWTH N V P D 35.3907 150,000 4,690,399 165,996,504
2017-04-25 4 Harvey Brian Nicholas M D 2.74 39,616 76,189
2017-03-21 4 BIOTECH GROWTH N V P D 35.8325 50,000 4,540,399 162,693,847
2017-03-20 4 Harvey Brian Nicholas M D 2.05 23,416 36,573
2017-03-17 4 BIOTECH GROWTH N V P D 38.4083 30,000 4,490,399 172,468,592
2017-03-15 4 BIOTECH GROWTH N V P D 39.956 44,469 4,460,399 178,219,702
2017-03-14 4 BIOTECH GROWTH N V P D 39.9993 17,252 4,415,930 176,634,109
2017-03-10 4 BIOTECH GROWTH N V P D 39.1673 38,279 4,398,678 172,284,341
2016-10-25 4 Ward Robert M D 7.8 10,000 15,000
2016-09-27 4 MPM BIOVENTURES III LLC J I -1,229,902 2,459,804
2016-09-27 4 GALAKATOS NICHOLAS J I -1,229,902 2,459,804
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)
RDUS: Radius Health Analysis and Research Report

2018-05-04 - Asif

Overview Radius Health is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. In April 2017, its first commercial product, TYMLOSTM (abaloparatide) injection, was approved by the U.S. Food and Drug Administration ("FDA") for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. In May 2017, the company commenced U.S. commercial sales of TYMLOS and, as of February 2018, TYMLOS was available and covered for approximately 259 million U.S. insured lives, representing approximately 86% of U.S. insured lives. In May 2017, the company also announced positive top-line results from its completed 24-month ACTIVExtend clinical trial for TYMLOS, which met all of ...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

2 Approaches To BioPharma: Interview With TPT Collaborators Amit Ghate And Zach Hartman

2018-09-10 seekingalpha
Thanks for joining us today! Welcome to Dr Zach Hartman and Amit Ghate, two well-known analysts on SeekingAlpha, and very luckily for us here at the Total Pharma Tracker, our two outstanding collaborators. (11-4)

Movers and Shakers for Aug. 10

2018-09-10 biospace
Agios Pharmaceuticals – Longtime Celgene veteran Jacqualyn (Jackie) Fouse has taken over the reins of Cambridge, Mass.-based Agios Pharmaceuticals. She will assume her the role of chief executive officer on Feb. 1, 2019, when current CEO David Schenkein steps down. Fouse has been serving on the Agios board of directors since December 2017. Fouse joined Celgene in 2010 and served as chief financial officer, and president of the company’s Hematology & Oncology franchise. (15-3)

Why Is Radius Health (RDUS) Down 11.8% Since Last Earnings Report?

2018-09-06 zacks
A month has gone by since the last earnings report for Radius Health (RDUS - Free Report) . Shares have lost about 11.8% in that time frame, underperforming the S&P 500. (4-0)

Closing Out My Radius Health Short With Lessons Learned

2018-08-24 seekingalpha
I closed out my RDUS short, which I had previously written up here at Seeking Alpha. (1-1)

Eloxx Pharmaceuticals' (ELOX) CEO Robert Ward on Q2 2018 Results - Earnings Call Transcript

2018-08-12 seekingalpha
Good afternoon, everyone, and welcome to Eloxx Pharmaceuticals Second Quarter 2018 Earnings Webcast and Conference Call. Today’s call is being recorded. At this time, I would like to turn the call over to Ms. Barbara Ryan, Eloxx’s Investor Relations Officer. Please begin. (3-3)